MedImmune (MDI.L), the global biologics arm of AstraZeneca (AZN, AZN.L), announced it has signed an in-licensing agreement with Progenics Pharmaceuticals, Inc. (PGNX) for Progenics' Clostridium difficile late-stage preclinical program. The agreement was led by MedImmune's Infectious Diseases & Vaccines Innovative Medicines Unit.
MedImmune's program will assess the potential efficacy and safety of treatment of the infection with investigational monoclonal antibodies targeting toxins that mediate the disease.
Financial details of the agreement were not disclosed.
For comments and feedback: editorial@rttnews.com